GOLD 2023 REPORT HIGHLIGHTS

The GOLD report is revised annually and has been used worldwide by healthcare professionals as a tool to implement
effective management programs based on local healthcare systems.

In the 2023 revision of the GOLD report includes several novel and important recommendations as follows:

i. A new definition of COPD has been proposed (Page 5)

ii. Chapter 1 has been rewritten to incorporate new background information on COPD and new strategies for
terminology and taxonomy
iii. A new section on Chronic Bronchitis has been added (Page 13)
iv. Additional information on Screening and Case-Finding has been included (Page 36)
v. The ABCD Assessment Tool has been revised to the ABE Assessment Tool to recognize the clinical relevance of
exacerbations, independent of the level of symptoms (Page 115)
vi. New information on Imaging and Computed Tomography (CT) has been included (Page 43)
vii. Vaccination Recommendations for people with COPD have been updated in line with current guidance from the

TE
CDC (Page 54)

U
viii. Further information on Therapeutic Interventions to Reduce COPD Mortality and a new table has been included

IB
TR
(Page 67)

IS
ix. A new definition of COPD Exacerbation and a new set of parameters to assess exacerbation severity at the point

D
of care has been included (Page 134)

R
x. Issues Related to Inhaled Delivery have been addressed (Page 69) O
PY

xi. Information on the topic of Adherence to Inhaled COPD Medications has been included (Page 71)
O
C

xii. A section on Tele-rehabilitation has been added (Page 76)

T

xiii. The section on Interventional & Surgical Therapies for COPD has been expanded (Page 82)
O
N

xiv. New information on the Choice of Inhaler Device and a new table has been added (Page 112)
O
-D

xv. The information and figures outlining Initial Pharmacological Treatment and Follow-up Pharmacological
LS

Treatment have been updated. In particular, the positioning of LABA+LAMA and of LABA+ICS has been changed
IA

(Page 115)
ER

xvi. Chapter 5 on the topic of Management of Exacerbations has been expanded to include details of possible
AT

alternative causes of symptoms and a new table on Diagnosis and Assessment (Page 136)
M

xvii. The sections on COPD and Comorbidities (Chapter 6) and COVID-19 and COPD (Chapter 7) have been updated
T
H

with the latest evidence.

IG
R
PY

GOLD has been fortunate to have a network of international distinguished health professionals from multiple disciplines.
O
C

Many of these experts have initiated investigations into the causes and prevalence of COPD in their countries and have
developed innovative approaches for the dissemination and implementation of the GOLD management strategy. The
GOLD initiative will continue to work with National Leaders and other interested healthcare professionals to bring COPD to
the attention of governments, public health officials, healthcare workers, and the general public, to raise awareness of the
burden of COPD and to develop programs for early detection, prevention and approaches to management.

Alvar G. Agusti, MD Claus Vogelmeier, MD

Chair, GOLD Board of Directors Chair, GOLD Science Committee
iv